Physician profile
Stephen L Avram
NPI 1174519623
$946.45
in general payments reported to CMS, 2019-2025
20 companies · $19.76 in 2025
The $19.76 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $185 · 2021: $216 · 2022: $182 · 2023: $74.43 · 2024: $87.04 · 2025: $19.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $181.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $131.89 | 2020-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.21 | 2020-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $113.19 | 2020-2021 | |
| Glaxosmithkline, LLC. | $109.73 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $70.38 | 2019-2023 | Repatha |
| Lilly USA, LLC | $56.84 | 2021-2023 | Jardiance |
| Abbott Laboratories | $38.73 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $36.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.14 | 2021 | |
| Amarin Pharma, INC. | $35.32 | 2019 | |
| Novo Nordisk INC | $31.08 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $26.75 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $24.79 | 2019 | |
| Merck Sharp & Dohme LLC | $24.00 | 2020 | |
| Exact Sciences Corporation | $22.87 | 2023 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16.33 | 2021 | |
| Ibsa Pharma INC. | $14.31 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.10 | 2019 | |
| Pfizer INC. | $13.62 | 2019 | |
| Redhill Biopharma INC. | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Avram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.